Psychedelic and ketamine research trials in the Netherlands
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
16 registered studies are counted in the Netherlands. By compound: 2 psilocybin, 2 MDMA, 4 LSD, 5 DMT, 5 5-MeO-DMT and 3 ketamine. By registry status: 4 recruiting, 1 not yet recruiting, 1 enrolling by invitation, 1 active, not recruiting, 7 completed, 1 terminated and 1 status not reported. By phase: 7 phase 1, 5 phase 2, 1 phase 3, 1 not applicable and 2 not reported. Reported start years run from 2010 (earliest) to 2026 (latest). Studies are linked to 12 institutions.
Country is taken from the research site linked to each registry record. A study counts once, and a study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
Recruiting now
5 of the 16 counted studies are listed in the registry as recruiting (4) or not yet recruiting (1), newest start first. Status is reported by study teams and can be out of date. PsychoactiveMap does not recruit, screen or refer anyone; eligibility and contact details are on each registry record.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Psilocybin-Assisted Psychotherapy for Veterans With PTSD | NCT07792538 | Not yet recruiting | Phase 2 | 2026-12-01 | ARQ National Psychotrauma Centre, Oegstgeest |
| Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients | NCT07706478 | Recruiting | Not reported | 2025-06-01 | Senz, Doorn |
| LSD to Improve Cluster Headache Impact Trial | NCT05477459 | Recruiting | Phase 2 | 2025-04-16 | Radboud University Medical Center, Leiden |
| The Impact of Psilocybin on Pain in Fibromyalgia Patients | NCT06368492 | Recruiting | Not applicable | 2024-05-03 | Maastricht University, Maastricht |
| Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study | NCT06161805 | Recruiting | Phase 3 | 2024-03-01 | Reinier de Graaf Groep, Delft |
At a glance
- 16 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 2 |
| MDMA | 2 |
| LSD | 4 |
| DMT | 5 |
| 5-MeO-DMT | 5 |
| Ketamine | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 4 | 25% |
| Not yet recruiting | 1 | 6% |
| Enrolling by invitation | 1 | 6% |
| Active, not recruiting | 1 | 6% |
| Completed | 7 | 44% |
| Terminated | 1 | 6% |
| Status not reported | 1 | 6% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 7 | 44% |
| Phase 2 | 5 | 31% |
| Phase 3 | 1 | 6% |
| Not applicable | 1 | 6% |
| Not reported | 2 | 13% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 6 |
| 2020 to 2023 | 6 |
| 2015 to 2019 | 3 |
| 2010 to 2014 | 1 |
All counted studies
All 16 counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Institution and city |
|---|---|---|---|---|---|
| Psilocybin-Assisted Psychotherapy for Veterans With PTSD | NCT07792538 | Not yet recruiting | Phase 2 | 2026-12-01 | ARQ National Psychotrauma Centre, Oegstgeest |
| Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients | NCT07706478 | Recruiting | Not reported | 2025-06-01 | Senz, Doorn |
| High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD | NCT06954025 | Enrolling by invitation | Phase 2 | 2025-05-16 | ARQ National Psychotrauma Centre, Oegstgeest |
| LSD to Improve Cluster Headache Impact Trial | NCT05477459 | Recruiting | Phase 2 | 2025-04-16 | Radboud University Medical Center, Leiden |
| The Impact of Psilocybin on Pain in Fibromyalgia Patients | NCT06368492 | Recruiting | Not applicable | 2024-05-03 | Maastricht University, Maastricht |
| Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study | NCT06161805 | Recruiting | Phase 3 | 2024-03-01 | Reinier de Graaf Groep, Delft |
| Phase 2 Clinical Trial of GH001 in Postpartum Depression | NCT05804708 | Terminated | Phase 2 | 2023-03-02 | GH Research Ireland Limited, Amsterdam |
| Single and Repeat Doses of DMT in Healthy Subjects | NCT05559931 | Active, not recruiting | Phase 1 | 2023-01-13 | Algernon Pharmaceuticals, Leiden |
| The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality | NCT05670184 | Status not reported | Phase 1 | 2023-01-01 | Maastricht University, Maastricht |
| Safety and Pharmacokinetics of GH002 in Healthy Volunteers | NCT05753956 | Completed | Phase 1 | 2022-12-22 | GH Research Ireland Limited, Groningen |
| Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial | NCT05200936 | Completed | Phase 2 | 2021-12-17 | Definium Therapeutics US, Inc., Maastricht |
| Pharmacokinetics of GH001 in Healthy Volunteers | NCT05163691 | Completed | Phase 1 | 2021-06-21 | GH Research Ireland Limited, Groningen |
| Clinical Study of GH001 in Depression | NCT04698603 | Completed | Phase 1 | 2019-11-12 | GH Research Ireland Limited, Maastricht |
| Safety of GH001 in Healthy Volunteers | NCT04640831 | Completed | Phase 1 | 2019-03-13 | GH Research Ireland Limited, Maastricht |
| A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder | NCT02919579 | Completed | Phase 1 | 2016-10-07 | Janssen Research & Development, LLC, Leiden |
| Naturalistic Study Into the Hangover Effects of MDMA | NCT01400204 | Completed | Not reported | 2010-12-01 | Utrecht Institute for Pharmaceutical Sciences, Utrecht |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ketamine
Condition hubs
Condition hubs that include studies counted in this country, with the number of those studies. Conditions are matched by keyword on registered titles, so one study can appear under more than one condition.
| Condition hub | Studies in this country |
|---|---|
| Depression | 4 |
| Post-traumatic stress disorder | 2 |
| Treatment-resistant depression | 2 |
| Chronic pain | 1 |
| Headache and migraine | 1 |
Other country hubs
United States | Canada | Switzerland | United Kingdom | France | Israel | Brazil | China | Australia | Austria | Germany | Spain | Sweden | Argentina | Belgium | Egypt | Mexico | Poland | Taiwan | Ireland | Czech Republic | Denmark | Finland